The DOI matches its Crossref record; 58 of the 58 references it cites were found in a registry or an index.
Dabigatran Etexilate: A New Oral Thrombin Inhibitor
Open accessAbstract
Onset of action 36-72 h 1 h 0.5-2 h Elimination half-life 20-60 h 4.5-7 h 12-14 h Duration of action 48-96 h 12 h 24 h Stable, predictable pharmacokinetics No Yes Yes Interactions with diet and alcohol Yes No No Monitoring INR every 1-4 wk Not monitored No routine monitoring required Dose adjustment Frequent Rarely required Rarely required
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dabigatran versus warfarin in patients with atrial fibrillation
Connolly, S. J., Ezekowitz, M. D., Yusuf, S., Eikelboom, J., Oldgren, J., Parekh, A., Pogue, J., Reilly, P. A., Themeles, E., Varrone, J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0905561 · Cited by 11,215
Hart, R. G., Pearce, L. A., & Aguilar, M. I. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-146-12-200706190-00007 · Cited by 4,793
Dabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism
Schulman, S., Kearon, C., Kakkar, A. K., Mismetti, P., Schellong, S., Eriksson, H., Baanstra, D., Schnee, J., & Goldhaber, S. Z. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0906598 · Cited by 2,583
Apixaban in patients with atrial fibrillation
Connolly, S. J., Eikelboom, J., Joyner, C., Diener, H.-C., Hart, R., Golitsyn, S., Flaker, G., Avezum, A., Hohnloser, S. H., Diaz, R., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1007432 · Cited by 2,483
Pharmacology and Management of the Vitamin K Antagonists
Ansell, J., Hirsh, J., Hylek, E., Jacobson, A., Crowther, M., & Palareti, G. (2008) · Chest · doi:10.1378/chest.08-0670 · Cited by 2,118
Effect of clopidogrel added to aspirin in patients with atrial fibrillation
The ACTIVE Investigators (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0901301 · Cited by 2,102
Estimation of the Warfarin Dose with Clinical and Pharmacogenetic Data
(2009) · New England Journal of Medicine · doi:10.1056/nejmoa0809329 · Cited by 1,577
Stangier, J., Haertter, S., Liesenfeld, K.-H., Wienen, W., Feuring, M., Clemens, A., & Ryn, J. V. (2010) · Thrombosis and Haemostasis · doi:10.1160/th09-11-0758 · Cited by 1,382
Wann, L. S., Curtis, A. B., January, C. T., Ellenbogen, K. A., Lowe, J. E., Estes, N. A. M., Page, R. L., Ezekowitz, M. D., Slotwiner, D. J., Jackman, W. M., et al. (2011) · Circulation · doi:10.1161/cir.0b013e3181fa3cf4 · Cited by 1,336
Weitz, J. I., Hudoba, M., Massel, D., Maraganore, J., & Hirsh, J. (1990) · Journal of Clinical Investigation · doi:10.1172/jci114723 · Cited by 1,123
Eriksson, B. I., Dahl, O. E., Rosencher, N., Kurth, A. A., van Dijk, C. N., Frostick, S. P., Prins, M. H., Hettiarachchi, R., Hantel, S., Schnee, J., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61445-7 · Cited by 1,116
Wallentin, L., Yusuf, S., Ezekowitz, M. D., Alings, M., Flather, M., Franzosi, M. G., Pais, P., Dans, A., Eikelboom, J., Oldgren, J., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61194-4 · Cited by 1,013
Self-citationERIKSSON, B. I., DAHL, O. E., ROSENCHER, N., KURTH, A. A., VAN DIJK, C. N., FROSTICK, S. P., KÄLEBO, P., CHRISTIANSEN, A. V., HANTEL, S., HETTIARACHCHI, R., et al. (2007) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2007.02748.x · Cited by 979
Stangier, J., Rathgen, K., Stähle, H., Gansser, D., & Roth, W. (2007) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2007.02899.x · Cited by 887
Warfarin, Aspirin, or Both after Myocardial Infarction
Hurlen, M., Abdelnoor, M., Smith, P., Erikssen, J., & Arnesen, H. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020496 · Cited by 846
Atrial fibrillation management: a prospective survey in ESC Member Countries
Nieuwlaat, R., Capucci, A., Camm, A. J., Olsson, S. B., Andresen, D., Davies, D. W., Cobbe, S., Breithardt, G., Le Heuzey, J.-Y., Prins, M. H., et al. (2005) · European Heart Journal · doi:10.1093/eurheartj/ehi505 · Cited by 829
Stangier, J., Rathgen, K., Stähle, H., & Mazur, D. (2010) · Clinical Pharmacokinetics · doi:10.2165/11318170-000000000-00000 · Cited by 722
Go, A. S., Hylek, E. M., Chang, Y., Phillips, K. A., Henault, L. E., Capra, A. M., Jensvold, N. G., Selby, J. V., & Singer, D. E. (2003) · JAMA · doi:10.1001/jama.290.20.2685 · Cited by 703
The Metabolism and Disposition of the Oral Direct Thrombin Inhibitor, Dabigatran, in Humans
Blech, S., Ebner, T., Ludwig-Schwellinger, E., Stangier, J., & Roth, W. (2008) · Drug Metabolism and Disposition · doi:10.1124/dmd.107.019083 · Cited by 689
Newly identified events in the RE-LY trial
Connolly, S. J., Ezekowitz, M. D., Yusuf, S., Reilly, P. A., & Wallentin, L. (2010) · New England Journal of Medicine · doi:10.1056/nejmc1007378 · Cited by 688
Di Nisio, M., Middeldorp, S., & Büller, H. R. (2005) · New England Journal of Medicine · doi:10.1056/nejmra044440 · Cited by 655
Stangier, J. (2008) · Clinical Pharmacokinetics · doi:10.2165/00003088-200847050-00001 · Cited by 655
(2009) · The Journal of Arthroplasty · doi:10.1016/j.arth.2008.01.132 · Cited by 631
Eriksson, B. I., Quinlan, D. J., & Weitz, J. I. (2009) · Clinical Pharmacokinetics · doi:10.2165/0003088-200948010-00001 · Cited by 522
Diener, H.-C., Connolly, S. J., Ezekowitz, M. D., Wallentin, L., Reilly, P. A., Yang, S., Xavier, D., Di Pasquale, G., & Yusuf, S. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70274-x · Cited by 451
Cost-Effectiveness of Dabigatran Compared With Warfarin for Stroke Prevention in Atrial Fibrillation
Freeman, J. V., Zhu, R. P., Owens, D. K., Garber, A. M., Hutton, D. W., Go, A. S., Wang, P. J., & Turakhia, M. P. (2011) · Annals of Internal Medicine · doi:10.7326/0003-4819-154-1-201101040-00289 · Cited by 429
Stangier, J., Stähle, H., Rathgen, K., & Fuhr, R. (2008) · Clinical Pharmacokinetics · doi:10.2165/00003088-200847010-00005 · Cited by 427
Ezekowitz, M. D., Reilly, P. A., Nehmiz, G., Simmers, T. A., Nagarakanti, R., Parcham-Azad, K., Pedersen, K. E., Lionetti, D. A., Stangier, J., & Wallentin, L. (2007) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2007.06.034 · Cited by 419
Baker, W. L., Cios, D. A., Sander, S. D., & Coleman, C. I. (2009) · Journal of Managed Care Pharmacy · doi:10.18553/jmcp.2009.15.3.244 · Cited by 411
Dahl, O., Huo, M., Kurth, A., Hantel, S., Hermansson, K., Schnee, J., Friedman, R., Eriksson, B., & for the RE-NOVATE II Study Group (2011) · Thrombosis and Haemostasis · doi:10.1160/th10-10-0679 · Cited by 401
Wann, L. S., Curtis, A. B., Ellenbogen, K. A., Estes, N. A. M., Ezekowitz, M. D., Jackman, W. M., January, C. T., Lowe, J. E., Page, R. L., Slotwiner, D. J., et al. (2011) · Circulation · doi:10.1161/cir.0b013e31820f14c0 · Cited by 399
Stangier, J., & Clemens, A. (2009) · Clinical and Applied Thrombosis/Hemostasis · doi:10.1177/1076029609343004 · Cited by 337
Ezekowitz, M. D., Connolly, S., Parekh, A., Reilly, P. A., Varrone, J., Wang, S., Oldgren, J., Themeles, E., Wallentin, L., & Yusuf, S. (2009) · American Heart Journal · doi:10.1016/j.ahj.2009.02.005 · Cited by 332
Use and Effectiveness of Warfarin in Medicare Beneficiaries With Atrial Fibrillation
Birman-Deych, E., Radford, M. J., Nilasena, D. S., & Gage, B. F. (2006) · Stroke · doi:10.1161/01.str.0000208294.46968.a4 · Cited by 301
Eckman, M. H., Rosand, J., Greenberg, S. M., & Gage, B. F. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-150-2-200901200-00005 · Cited by 283
Weitz, J. I., Hirsh, J., & Samama, M. M. (2008) · Chest · doi:10.1378/chest.08-0673 · Cited by 262
Eikelboom, J. W., & Weitz, J. I. (2010) · Circulation · doi:10.1161/circulationaha.109.853119 · Cited by 245
Self-citationSun, J. C., Davidson, M. J., Lamy, A., & Eikelboom, J. W. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60780-7 · Cited by 241
Self-citationDabigatran: An Oral Novel Potent Reversible Nonpeptide Inhibitor of Thrombin
Eisert, W. G., Hauel, N., Stangier, J., Wienen, W., Clemens, A., & van Ryn, J. (2010) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.110.203604 · Cited by 216
Weitz, J. I., Leslie, B., & Hudoba, M. (1998) · Circulation · doi:10.1161/01.cir.97.6.544 · Cited by 194
Novel Oral Factor Xa and Thrombin Inhibitors in the Management of Thromboembolism
Eriksson, B. I., Quinlan, D. J., & Eikelboom, J. W. (2011) · Annual Review of Medicine · doi:10.1146/annurev-med-062209-095159 · Cited by 194
Self-citationStangier, J., Stähle, H., Rathgen, K., Roth, W., & Shakeri‐Nejad, K. (2008) · The Journal of Clinical Pharmacology · doi:10.1177/0091270008324179 · Cited by 177
New Anticoagulants for Treatment of Venous Thromboembolism
Gross, P. L., & Weitz, J. I. (2008) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.108.162677 · Cited by 177
Lip, G. Y. H., Noack, H., Clemens, A., Plumb, J. M., & Roskell, N. (2010) · Thrombosis and Haemostasis · doi:10.1160/th10-10-0642 · Cited by 121
Liesenfeld, K., Schäfer, H. G., Trocóniz, I. F., Tillmann, C., Eriksson, B. I., & Stangier, J. (2006) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2006.02667.x · Cited by 118
Baetz, B., & Spinler, S. A. (2008) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.28.11.1354 · Cited by 107
Does Warfarin for Stroke Thromboprophylaxis Protect Against MI in Atrial Fibrillation Patients?
Lip, G. Y. H., & Lane, D. A. (2010) · The American Journal of Medicine · doi:10.1016/j.amjmed.2010.01.031 · Cited by 103
Trocóniz, I. F., Tillmann, C., Liesenfeld, K., Schäfer, H. G., & Stangier, J. (2007) · The Journal of Clinical Pharmacology · doi:10.1177/0091270006297228 · Cited by 97
Coadministration of Dabigatran Etexilate and Atorvastatin
Stangier, J., Rathgen, K., Stähle, H., Reseski, K., Körnicke, T., & Roth, W. (2009) · American Journal of Cardiovascular Drugs · doi:10.1007/bf03256595 · Cited by 96
Hankey, G. J., & Eikelboom, J. W. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70038-7 · Cited by 87
Self-citationThomas, E., Wagner, K., & Wienen, W. (2010) · Drug Metabolism and Disposition · doi:10.1124/dmd.110.033696 · Cited by 86
Stroke Risk and Antithrombotic Strategies in Atrial Fibrillation
MEDI, C., Hankey, G. J., & Freedman, S. B. (2010) · Stroke · doi:10.1161/strokeaha.110.589218 · Cited by 81
Self-citationWolowacz, S. E., Roskell, N., Maciver, F., Beard, S. M., Robinson, P. A., Plumb, J. M., Dolan, G., & Brenkel, I. J. (2009) · Clinical Therapeutics · doi:10.1016/j.clinthera.2009.01.001 · Cited by 80
Novel Anticoagulants for Stroke Prevention in Atrial Fibrillation
Schirmer, S. H., Baumhäkel, M., Neuberger, H., Hohnloser, S. H., Gelder, I. C. V., Lip, G. Y. H., & Böhm, M. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.09.017 · Cited by 71
The frequency of prescription of P‐glycoprotein‐affecting drugs in atrial fibrillation
Jungbauer, L., Dobias, C., Stöllberger, C., & Weidinger, F. F. (2010) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2010.03943.x · Cited by 32
Sergent, O., Ekroos, K., Lefeuvre‐Orfila, L., Rissel, M., Forsberg, G., Oscarsson, J., Andersson, T. B., & Lagadic‐Gossmann, D. (2009) · Toxicology in Vitro · doi:10.1016/j.tiv.2009.07.019 · Cited by 31
What do the results of the PRoFESS trial teach us?
Hankey, G. J., & Eikelboom, J. W. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(08)70199-6 · Cited by 8
Self-citation
Cited by
Demaerschalk, B. M., Kleindorfer, D. O., Adeoye, O. M., Demchuk, A. M., Fugate, J. E., Grotta, J. C., Khalessi, A. A., Levy, E. I., Palesch, Y. Y., Prabhakaran, S., et al. (2016) · Stroke · doi:10.1161/str.0000000000000086 · Cited by 670
Healey, J. S., Eikelboom, J., Douketis, J., Wallentin, L., Oldgren, J., Yang, S., Themeles, E., Heidbuchel, H., Avezum, A., Reilly, P., et al. (2012) · Circulation · doi:10.1161/circulationaha.111.090464 · Cited by 541
Self-citationManagement of Antithrombotic Therapy in Patients Undergoing Invasive Procedures
Baron, T. H., Kamath, P. S., & McBane, R. D. (2013) · New England Journal of Medicine · doi:10.1056/nejmra1206531 · Cited by 457
Lakkireddy, D., Reddy, Y. M., Di Biase, L., Vanga, S. R., Santangeli, P., Swarup, V., Pimentel, R., Mansour, M. C., D'Avila, A., Sanchez, J. E., et al. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2011.12.014 · Cited by 356
Guidance for the practical management of the direct oral anticoagulants (DOACs) in VTE treatment
Burnett, A. E., Mahan, C. E., Vazquez, S. R., Oertel, L. B., Garcia, D. A., & Ansell, J. (2016) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-015-1310-7 · Cited by 333
Metadata
- Authors
- Hankey, G. J., & Eikelboom, J. W.
- Venue
- Circulation
- Published
- 2011-04-05
- Volume
- 123
- Issue
- 13
- Pages
- 1436-1450
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W2130909191
- Cited by
- 348
- References
- 58
- FWCI
- 31.79
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.